#GLP-1 agonists

[trendynewsnow]

Amgen's Experimental Obesity Drug MariTide Shows Promising Weight Loss Results

Amgen’s Promising Experimental Obesity Drug Shows Significant Weight Loss The pharmaceutical manufacturer Amgen made headlines on Tuesday by announcing that its experimental obesity medication, branded as MariTide, has demonstrated remarkable efficacy in clinical trials, helping patients shed an average of up to 20 percent of their body weight over the course of a year. This innovative drug is…

[andmaybegayer]

sometimes I forget that while many of my opinions straightforwardly track from the inscrutable memetic subcultures I subscribe to, they're inscrutable memetic subcultures so offline normal people do not expect some of these opinions to go together.

[transmutationisms]

what are your thoughts on the current ozempic/semaglutide ‘craze’ ? weight loss drugs are obviously nothing new but it does seem like these ones are being marketed as being uniquely ‘safe’ with some doctors/medical experts/shareholders hoping that they’ll be prescribed to everyone eventually (red flag to me right there lol)

i don't know enough about the pharmacology of diabetes to judge the consequences of these drugs for their initial purpose, but as weight loss drugs, yeah i find them pretty concerning. i mean, they're just appetite suppressants that work by fucking with the endocrine system rather than (as with most prev weight loss drugs) being stimulants. so, as far as i can tell the claims that they're uniquely or newly safe are coming from the fact that they don't cause the side effects that stimulants would (racing heart and so forth). but the side effects people are reporting are just like... the effects of chronic food restriction lmao. like, losing weight by eating less is kinda the same process no matter what.... it's starvation at a subclinical level, or rather, starvation prescribed by the clinic and experienced as consciously unconcerning because of the drug's effect on the endocrine system. the fact that people are experiencing micronutrient deficiencies, bone density loss, hair loss, the same skin/nail problems as with any other self-starvers, and so forth doesn't bother these doctors because in their minds weight loss is inherently 'healthy' and so ipso facto the biological effects of energy deprivation are nbd. it's pretty ghoulish.

i don't think these drugs have been on the market long enough to say much conclusively about their long-term effect, as in, if you stay on them forever do they actually keep you weight-suppressed forever. as far as i can tell most users do seem to naturally settle at a weight that is at least temporarily stable, suggesting it is a local set point, just one that's lower than the one they were at prior to pharmacological intervention. so maybe the drugs would keep you there long-term if you stayed on them---gold mine for the pharma companies, obviously. certainly the data are showing that people will pretty inevitably regain the weight if they stop the drugs, though. (as with any weight loss studies, there will ofc be a very very tiny percentage of the population who do not regain, because they have 'learned' how to continue energy-restricting at the required level to maintain the loss long-term; without the drugs this will ofc be pretty miserable and uh, no longer distinguishable in any way from regular old self-starvation.)

so i mean, basically what these drugs promise is actual appetite suppression, and tbf they do deliver on that (for most people; reports are that some users just don't lose appetite/weight on them). but the 'safety' claims are ignoring the fact that energy deprivation is inherently biologically stressful, and in the long term who really knows what fucking around with yr metabolism/endocrine system like this will do. i certainly don't fault people for seeking out weight loss drugs, ie wanting to be thin in a social situation that economically and socially punishes fatness! but i absolutely do think the doctors pushing these drugs are fucking despicable, and are lying/in denial about the simple fact that undereating is causing their patients to experience negative health effects side effects, plus whatever the long-term netabolic/endocrine consequences may be.

[pr0cyonid]

Man I'm sorry I keep talking about my weight loss so option, but I just FEEL so much better, both physically and mentally. I saw my parents this weekend and my mom said she can notice a difference. My boyfriend notices a difference. I notice a difference. My friends notice a difference. I don't feel tired all the time and my joints are starting to hurt less.

This has been SO hard for me. I've been trying to lose this weight for years. I've been doing everything right, and it just won't go away - and even my doctors have agreed with me on this. It's so nice to have found something that finally works because it's so gutting to feel like you're putting in all the work to get no results

[scientificinquirer-blog]

Expanding access to weight-loss drugs could save thousands of lives a year

 Expanding access to new, highly effective weight-loss medications could prevent more than 40,000 deaths a year in the United States, according to a new study led by researchers at Yale School of Public Health and the University of Florida. The findings highlight the critical need to remove existing barriers that are hindering people’s access to effective weight loss treatments and impeding…

[nfuzewellness]

Exploring Semaglutide and Trizeptride: Contrasting Weight Loss Injections

Discover the differences between Semaglutide and Trizeptride, two innovative GLP-1 receptor agonists for weight loss. Learn about their mechanisms, benefits, and which might be right for your obesity treatment needs in Edwardsville.

[shrinksinsneakers]

A recent study published in JAMA Network Open investigated the relationship between semaglutide, a medication commonly used for type 2 diabetes (T2D), and the risk of opioid overdose in patients with both T2D and opioid use disorder (OUD). 

[mehmetyildizmelbourne-blog]

Let's Talk About GLP-1 receptor agonists (GLP1-RAs)

GLP-1 receptor agonists (GLP1-RAs), including Tirzepatide and Semaglutide, are showing promise not just in managing type 2 diabetes but also in addressing inflammatory and neurodegenerative conditions. These medications have demonstrated benefits beyond blood sugar control, such as anti-inflammatory and neuroprotective effects. Research indicates that they may potentially aid in the treatment of…

[voidthewanderer]

Ughhhh why the fuck is the humidity so high I’m so itchy

[mitalipingale]

https://social.studentb.eu/read-blog/184594_glp-1-receptor-agonist-market-size-analysis-and-forecast-2031.html

The GLP-1 Receptor Agonist Market in 2023 is US$ 14.44 billion, and is expected to reach US$ 23.58 billion by 2031 at a CAGR of 6.32%.

[trendbuzzz]

6 Week Belly Ozempic Weight Loss Before and After

In a world where countless weight loss methods promise quick fixes, finding an approach that not only delivers results but also targets that stubborn belly fat can feel like an elusive quest. But what if we told you that a 6 Week Belly Ozempic Weight Loss Before and After challenge could be the key to your long-awaited transformation? Hold on tight because we are about to go on a journey that…

[transmutationisms]

about ozempic, i don’t have time to look for it right now but i have seen multiple articles about how the mechanism that the drug works by is causing people to aspirate during surgery because the normal fasting period doesn’t apply to them since their stomach stays full even after the pre surgery fasting period. even being off the medication for a week can still cause problems with aspiration.

wow i had not heard anything about this but yea you're right, here's an overview from the american society of anaesthesiologists:

The GLP-1 agonists are associated with adverse gastrointestinal effects such as nausea, vomiting and delayed gastric emptying (see table). [...] Based on recent anecdotal reports, there are concerns that delayed gastric emptying from GLP-1 agonists can increase the risk of regurgitation and pulmonary aspiration of gastric contents during general anesthesia and deep sedation.12-14 The presence of adverse gastrointestinal symptoms (nausea, vomiting, dyspepsia, abdominal distension) in patients taking GLP-1 agonists are predictive of increased residual gastric contents.12

this is pretty preliminary ("The evidence to provide guidance for preoperative management of these drugs to prevent regurgitation and pulmonary aspiration of gastric contents is sparse limited [sic] only to several case reports") but sufficient that their official recommendation is to treat patients needing emergency procedures as 'full stomach', hold GLP-1 agonists for a week prior to scheduled procedures, and delay procedures if patients are experiencing GI symptoms day-of. but this overview also says they don't have sufficient information about gastric emptying rates in patients taking these drugs, so the 1-week recommendation is kinda guesswork at this point!

also delayed gastric emptying is literally so miserable in general im sorry to anyone experiencing this

[j0hn-appleseed]

[myblogscmi]

Navigating The Future: Trends And Challenges In The GLP-1 Receptor Agonist Market

The GLP-1 receptor agonist market, a critical segment of the pharmaceutical industry, is poised for significant transformations as it continues to address the needs of patients with type 2 diabetes. This dynamic market has seen impressive growth and innovation, but it also faces unique challenges that warrant attention and proactive strategies. Combination Therapies: Combination therapies, involving the use of GLP-1 receptor agonists in conjunction with other diabetes medications, are becoming more common. This approach can provide synergistic effects and better blood sugar control, offering patients comprehensive treatment strategies.

Personalized Treatment: The concept of personalized medicine is gaining traction in the GLP-1 Receptor Agonist Market. Advances in genetics and molecular biology are enabling healthcare providers to tailor treatment plans to individual patients' needs, maximizing the effectiveness of these medications.

Digital Health Solutions: The integration of digital health solutions, such as mobile apps and wearable devices, is transforming how patients and healthcare professionals manage diabetes. These technologies can assist with medication adherence, track blood sugar levels, and provide real-time insights into patients' health status.

Affordability and Access: Despite the market's growth, affordability and access to GLP-1 receptor agonists remain challenges for many patients. Developing cost-effective options and collaborating with healthcare systems to improve access will be crucial to ensuring equitable treatment for all. Long-term Safety and Efficacy: While the cardiovascular benefits of GLP-1 receptor agonists are well-established, the long-term safety and efficacy of these medications require continuous monitoring. Post-market surveillance and research are essential to identify any potential adverse effects over extended periods.

Patient Education: Educating patients about the benefits, proper usage, and potential side effects of GLP-1 receptor agonists is vital. Empowering patients to make informed decisions about their treatment can improve adherence and overall treatment outcomes.

As the GLP-1 Receptor Agonist Market navigates the future, collaboration among pharmaceutical companies, healthcare providers, regulators, and patient advocacy groups will be instrumental. By working together, these stakeholders can overcome challenges and capitalize on emerging trends to improve the lives of individuals with type 2 diabetes.

In conclusion, the GLP-1 receptor agonist market's journey is one of growth, innovation, and adaptation. While trends like personalized treatment and digital health solutions hold promise, addressing challenges related to affordability, safety, and patient education remains crucial. Through sustained efforts and a patient-centered approach, the market can continue to evolve and positively impact the lives of millions affected by type 2 diabetes.

[wellhealthhub]

Diabetes Medicine: An In-depth Guide to Managing Diabetes

Looking for detailed information on diabetes medicine? This extensive article covers all aspects of effective diabetes management, including a wide range of treatments and medications. Gain insights from experts and real-life experiences. Introduction: Recognizing the Vitality of Diabetes Medicine Diabetes, a pervasive chronic condition afflicting millions worldwide, arises from impaired blood…